News & Events

Targeting KRAS Mutations in Cancer Therapy

Targeting KRAS Mutations in Cancer Therapy

How KRAS Inhibitors Are Transforming Cancer Therapy

How KRAS Inhibitors Are Transforming Cancer Therapy

Practice Updates in Lung Cancer Stem From Biomarker Testing and Up-Front Immunotherapy

Practice Updates in Lung Cancer Stem From Biomarker Testing and Up-Front Immunotherapy

Circulating tumor DNA dynamics reveal KRAS G12C mutation heterogeneity and response to treatment with the KRAS G12C inhibitor divarasib in solid tumors

Circulating tumor DNA dynamics reveal KRAS G12C mutation heterogeneity and response to treatment with the KRAS G12C inhibitor divarasib in solid tumors

Roche's divarasib to take on approved KRAS inhibitors in Phase III study

Roche's divarasib to take on approved KRAS inhibitors in Phase III study

KRYSTAL-12 boosts adagrasib as 2L Tx alternative for KRASG12C-mutated NSCLC

KRYSTAL-12 boosts adagrasib as 2L Tx alternative for KRASG12C-mutated NSCLC

Lung Cancer Expert at ASCO: From Fatal to 'Chronic Disease'

Lung Cancer Expert at ASCO: From Fatal to 'Chronic Disease'

KRYSTAL-12: Adagrasib Significantly Improved PFS, Response in Certain Form of NSCLC

KRYSTAL-12: Adagrasib Significantly Improved PFS, Response in Certain Form of NSCLC

KRAS and TP53 co-mutation predicts benefit of immune checkpoint blockade in lung adenocarcinoma

KRAS and TP53 co-mutation predicts benefit of immune checkpoint blockade in lung adenocarcinoma